二氢杨梅素对Saos-2细胞所致原位骨肉瘤的治疗作用研究  

Therapeutic effect of dihydromyricetin on orthotopic osteosarcoma induced by Saos-2 cells

作　　者：范凯健 吴菁[2] 王磊[3] 许冰馨 王婷玉[2] FAN Kai-jian;WU Jing;WANG Lei;XU Bing-xin;WANG Ting-yu(Department of Pharmacy,Mental Health Center of Chongming District,Shanghai 202150;Department of Pharmacy,Shanghai Ninth People’s Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai 200011;Department of Orthopaedic Surgery,Shanghai Ninth People’s Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai 200011)

机构地区：[1]上海市崇明区精神卫生中心药剂科,上海202150 [2]上海交通大学医学院附属第九人民医院药剂科,上海200011 [3]上海交通大学医学院附属第九人民医院骨科,上海200011

出　　处：《中南药学》2020年第7期1103-1106,共4页Central South Pharmacy

基　　金：国家自然科学基金(No.81301531,No.81572104,No.81874011);上海市科委科研项目(No.18140903502)。

摘　　要：目的观察二氢杨梅素对Saos-2细胞所致的原位骨肉瘤的治疗作用。方法 24只BALB/c裸鼠随机分为模型组、低剂量组、高剂量组。对所有裸鼠于左后肢根部皮下注射Saos-2细胞进行造模。造模后第7日,对除模型组外裸鼠腹腔注射二氢杨梅素,每周3次,连续给药6周。给药结束后对肿块进行拍照和测量。结果造模后注射部位出现明显的肿块。与模型组相比,二氢杨梅素能够显著抑制骨肉瘤的发展(P<0.01),且高剂量更为明显。结论二氢杨梅素具有明显的抗骨肉瘤作用,可能是治疗骨肉瘤的潜在药物。Objective To determine the effect of dihydromyricetin(DMY)on orthotopic osteosarcoma caused by Saos-2 cells.Methods We randomly divided 24 BALB/c nude mice into a model group,a low-dose group(low DMY),and a high-dose group(high DMY).All nude mice were subcutaneously injected Saos-2 cells in the left hindlimb root.Seven days after the modeling,dihydromyricetin was injected intraperitoneally into the nude mice except the model group,3 times a week for 6 weeks.The tumors were photographed and measured one day after the administration.Results A significant tumor appeared at the injection site after the modeling.Compared with the model group,dihydromyricetin significantly inhibited the development of osteosarcoma(P<0.01),and high dose was more effective.Conclusion Dihydromyricetin has obvious anti-osteosarcoma effect and may be a potential drug for osteosarcoma.

关 键 词：骨肉瘤 二氢杨梅素 SAOS-2细胞 裸鼠 

分 类 号：R286[医药卫生—中药学]